Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - palbociclib - capsule - 75mg

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - palbociclib - capsule - 100mg

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - palbociclib - capsule - 125mg

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - amlodipine besilate - capsule, hard - 10 milligram(s) - amlodipine

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nitrofurantoin, quantity: 100 mg - capsule, hard - excipient ingredients: maize starch; purified talc; lactose monohydrate; gelatin; quinoline yellow; titanium dioxide; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; simethicone - indications as at 1 january 1991 : treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nitrofurantoin, quantity: 50 mg - capsule, hard - excipient ingredients: gelatin; maize starch; quinoline yellow; titanium dioxide; lactose monohydrate; purified talc; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - indications as at 1 january 1991 : treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - rifabutin, quantity: 150 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; magnesium stearate; silicon dioxide; iron oxide red; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid; povidone; tert-butyl alcohol; sodium hydroxide - mycobutin is indicated for: the prophylaxis of m.avium-intracellulare complex (mac) infections in patients with advanced hiv infection (cd4 counts lower than 200/ul); the treatment of infections caused by mac and other atypical mycobacteria, including in immunocompromised patients; the treatment of chronic multi-drug resistant pulmonary tuberculosis in the presence of rifampicin resistant, rifabutin-sensitive m.tuberculosis strains; the treatment of newly diagnosed pulmonary tuberculosis in the presence of rifampicin resistant, rifabutin sensitive m.tuberculosis strains. in accordance with the commonly accepted criteria for the treatment of mycobacterial infections, mycobutin should always be given in combination with other anti-mycobacterial drugs not belonging to the family of rifamycins.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 150 mg - capsule, hard - excipient ingredients: patent blue v; maize starch; gelatin; titanium dioxide; colloidal anhydrous silica; magnesium stearate; sodium lauryl sulfate; lactose monohydrate; butan-1-ol; shellac; industrial methylated spirit; dimeticone 1510; iron oxide black; lecithin; propylene glycol; isopropyl alcohol; purified water; ethanol; strong ammonia solution; potassium hydroxide - indications as at 21 june 2005 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of exten

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

cipla usa inc. - pregabalin (unii: 55jg375s6m) (pregabalin - unii:55jg375s6m) - pregabalin capsules are indicated for: - management of neuropathic pain associated with diabetic peripheral neuropathy - management of postherpetic neuralgia - adjunctive therapy for the treatment of partial-onset seizures in patients 4 years of age and older - management of fibromyalgia - management of neuropathic pain associated with spinal cord injury pediatric use information is approved for pfizer's lyrica (pregabalin) capsules and oral solution products. however, due to pfizer's marketing exclusivity rights, this drug product is not labeled with that pediatric information. pregabalin capsules are contraindicated in patients with known hypersensitivity to pregabalin or any of its components. angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [see warnings and precautions (5.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to pregabalin capsules during pregnancy. to provide informa

Սինգապուր - անգլերեն - HSA (Health Sciences Authority)

pfizer private limited - talazoparib tosylate eqv talazoparib - capsule - talazoparib tosylate eqv talazoparib 0.25 mg